Informatie:
Fout:
ID
34426
Beschrijving
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations; ODM derived from: https://clinicaltrials.gov/show/NCT01287754
Link
https://clinicaltrials.gov/show/NCT01287754
Trefwoorden
Versies (1)
- 17-01-19 17-01-19 -
Houder van rechten
GSK group of companies
Geüploaded op
17 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Non-Small Cell Lung Cancer NCT01287754
Eligibility Non-Small Cell Lung Cancer NCT01287754
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer NCT01287754
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
adult patients, >/=18 years of age
boolean
ID.2
Item
locally advanced or metastatic (stage iii/iv) non-small cell lung cancer with egfr mutations
boolean
ID.3
Item
measurable disease according to recist criteria
boolean
ID.4
Item
ecog performance status 0-2
boolean
ID.5
Item
adequate haematological, renal and liver function
boolean
ID.6
Item
previous chemotherapy or therapy against egfr for metastatic disease
boolean
ID.7
Item
history of another malignancy, except for in situ carcinoma of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis
boolean
ID.8
Item
symptomatic cerebral metastases
boolean
ID.9
Item
pre-existing parenchymal lung disease such as pulmonary fibrosis
boolean
ID.10
Item
concomitant use of coumarins
boolean